ID   Z-138
AC   CVCL_B077
SY   Z138
DR   EFO; EFO_0005479
DR   ATCC; CRL-3001
DR   BioSample; SAMN03471023
DR   cancercelllines; CVCL_B077
DR   ChEMBL-Cells; CHEMBL4483125
DR   ChEMBL-Targets; CHEMBL4483276
DR   Cosmic; 2078183
DR   Cosmic; 2088021
DR   Cosmic; 2296992
DR   Cosmic; 2756238
DR   GEO; GSM115807
DR   GEO; GSM629502
DR   GEO; GSM629503
DR   GEO; GSM1044974
DR   GEO; GSM1044975
DR   GEO; GSM1044976
DR   GEO; GSM1044977
DR   GEO; GSM1266779
DR   GEO; GSM1266780
DR   GEO; GSM1266787
DR   GEO; GSM1266788
DR   GEO; GSM1266789
DR   GEO; GSM1266790
DR   GEO; GSM1266791
DR   GEO; GSM1266792
DR   GEO; GSM2322624
DR   Lonza; 1605
DR   Progenetix; CVCL_B077
DR   PubChem_Cell_line; CVCL_B077
DR   Wikidata; Q54995848
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9669839;
RX   PubMed=16183118;
RX   PubMed=16203034;
RX   PubMed=16960149;
RX   PubMed=21746927;
RX   PubMed=24362935;
RX   PubMed=25315077;
RX   PubMed=25688540;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26194763;
RX   PubMed=27697772;
RX   PubMed=29666304;
CC   Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC   Population: Caucasian.
CC   Doubling time: 24 hours (PubMed=25315077).
CC   HLA typing: A*01:01,23:01; B*08:01,44:05; C*02:02,07:06; DQA1*05:01,01:01; DQB1*05:01,02:01; DRB1*03:01,01:01 (PubMed=25960936).
CC   HLA typing: A*01,23; B*08,44; C*02,07 (PubMed=25688540).
CC   Sequence variation: Mutation; HGNC; 12032; TRAF2; Simple; p.Trp114Ter (c.341G>A); Zygosity=Unspecified (PubMed=24362935).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: HLA*C loci for PubMed=24362935 was incorrect, modified version submitted by Pellat-Deceunynck C.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): ATCC; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,12
ST   D16S539: 11
ST   D18S51: 14,18
ST   D21S11: 30,32.2
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D7S820: 8
ST   D8S1179: 8,13
ST   FGA: 20,22
ST   Penta D: 13,15
ST   Penta E: 7,18
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 15,18
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   70Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 27
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=9669839; DOI=10.1016/S0145-2126(97)00191-4;
RA   Estrov Z., Talpaz M., Ku S., Harris D., Van Q., Beran M.,
RA   Hirsch-Ginsberg C.F., Huh Y., Yee G., Kurzrock R.;
RT   "Z-138: a new mature B-cell acute lymphoblastic leukemia cell line
RT   from a patient with transformed chronic lymphocytic leukemia.";
RL   Leuk. Res. 22:341-353(1998).
//
RX   PubMed=16183118; DOI=10.1016/j.leukres.2005.08.016;
RA   Tucker C.A., Bebb G., Klasa R.J., Chhanabhai M., Lestou V.S.,
RA   Horsman D.E., Gascoyne R.D., Wiestner A., Masin D., Bally M.,
RA   Williams M.E.;
RT   "Four human t(11;14)(q13;q32)-containing cell lines having classic and
RT   variant features of mantle cell lymphoma.";
RL   Leuk. Res. 30:449-457(2006).
//
RX   PubMed=16203034; DOI=10.1016/j.leukres.2005.08.026;
RA   Medeiros L.J., Estrov Z., Rassidakis G.Z.;
RT   "Z-138 cell line was derived from a patient with blastoid variant
RT   mantle cell lymphoma.";
RL   Leuk. Res. 30:497-501(2006).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=21746927; DOI=10.1073/pnas.1018941108;
RA   Beltran E., Fresquet V., Martinez-Useros J., Richter-Larrea J.A.,
RA   Sagardoy A., Sesma I., Almada L.L., Montes-Moreno S., Siebert R.,
RA   Gesk S., Calasanz M.J., Malumbres R., Rieger M., Prosper F.,
RA   Lossos I.S., Piris M.A., Fernandez-Zapico M.E.,
RA   Martinez-Climent J.A.;
RT   "A cyclin-D1 interaction with BAX underlies its oncogenic role and
RT   potential as a therapeutic target in mantle cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:12461-12466(2011).
//
RX   PubMed=24362935; DOI=10.1038/nm.3435;
RA   Rahal R., Frick M., Romero R., Korn J.M., Kridel R., Chan F.C.,
RA   Meissner B., Bhang H.-E.C., Ruddy D., Kauffmann A., Farsidjani A.,
RA   Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S.,
RA   Dietze K., Dorken B., Steidl C., Tzankov A., Hummel M., Monahan J.,
RA   Morrissey M.P., Fritsch C., Sellers W.R., Cooke V.G., Gascoyne R.D.,
RA   Lenz G., Stegmeier F.;
RT   "Pharmacological and genomic profiling identifies NF-kappaB-targeted
RT   treatment strategies for mantle cell lymphoma.";
RL   Nat. Med. 20:87-92(2014).
//
RX   PubMed=25315077; DOI=10.3109/10428194.2014.970548;
RA   Fogli L.K., Williams M.E., Connors J.M., Reid Y.A., Brown K.,
RA   O'Connor O.A.;
RT   "Development and characterization of a Mantle Cell Lymphoma Cell Bank
RT   in the American Type Culture Collection.";
RL   Leuk. Lymphoma 56:2114-2122(2015).
//
RX   PubMed=25688540; DOI=10.1002/cyto.a.22643;
RA   Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P.,
RA   Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A.,
RA   Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.;
RT   "A simple flow cytometry-based barcode for routine authentication of
RT   multiple myeloma and mantle cell lymphoma cell lines.";
RL   Cytometry A 87:285-288(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26194763; DOI=10.1182/blood-2015-01-624585;
RA   Bhatt S., Matthews J., Parvin S., Sarosiek K.A., Zhao D.-K., Jiang X.-Y.,
RA   Isik E., Letai A.G., Lossos I.S.;
RT   "Direct and immune-mediated cytotoxicity of interleukin-21 contributes
RT   to antitumor effects in mantle cell lymphoma.";
RL   Blood 126:1555-1564(2015).
//
RX   PubMed=27697772; DOI=10.1182/blood-2016-06-720490;
RA   Chiron D., Bellanger C., Papin A., Tessoulin B., Dousset C., Maiga S.,
RA   Moreau A., Esbelin J., Trichet V., Chen-Kiang S., Moreau P.,
RA   Touzeau C., Le Gouill S., Amiot M., Pellat-Deceunynck C.;
RT   "Rational targeted therapies to overcome microenvironment-dependent
RT   expansion of mantle cell lymphoma.";
RL   Blood 128:2808-2818(2016).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//